Latest News
Carrick Therapeutics to Present Clinical Data on Samuraciclib (CT7001), a First-In-Class Inhibitor of CDK7, at the 2021 San Antonio Breast Cancer Symposium
November 23, 2021 Read more
Carrick Therapeutics Presents Encouraging Initial Efficacy for Samuraciclib (CT- 7001) in Combination with Fulvestrant in Advanced HR+, HER2- Breast Cancer Patients at ESMO Congress 2021
September 16, 2021 Read more
Carrick Therapeutics to Present First Clinical Data on Samuraciclib (CT-7001), a First-In-Class Inhibitor of CDK7 at the European Society for Medical Oncology (ESMO) Congress 2021
Aug 17, 2021
Carrick Therapeutics Receives FDA Fast Track Designations for Two Samuraciclib Combinations for the Treatment of HR+, HER2- Advanced Breast Cancer and Locally Advanced or Metastatic Triple Negative Breast Cancer
Aug 16, 2021
Carrick Therapeutics Announces Collaboration with Roche to Evaluate Novel Samuraciclib Combination to Treat HR+ Breast Cancer
Aug 2, 2021
Carrick Therapeutics announces plan to establish US operations and appointment of Tim Pearson as CEO
Jun 28, 2019
Carrick Therapeutics in the media
Women Mean Business: Carrick Therapeutics – EY Emerging Entrepreneur Award Winner
Oct 29, 2018
Carrick Therapeutics in-licenses targeted ovarian cancer treatment from BTG and appoints George Golumbeski as Chairman
Oct 11, 2018
Ex-Celgene dealmaker George Golumbeski joins up to guide Carrick on its cancer drug quest — and maybe an IPO as well
Oct 11, 2018
News Medical: New class of drug holds potential to help patients with treatment-resistant cancers
Apr 10, 2018
Creating a premier oncology company in Europe – BioPharma Dealmakers / Nature magazine
March, 2018
Carrick Therapeutics announces first patient dosed in phase 1 clinical trial of its oral CDK7 inhibitor: CT7001
Nov 30, 2017
Labiotech.eu: Interviews Top Women in Biotech
Nov 7, 2017
Say Hello to the Top Female Entrepreneurs in European Biotech. Read more
Biotech and Money: Winner’s Spotlight – Carrick Therapeutics
Nov 3, 2017
An interview with Elaine Sullivan Co-Founder & CEO Carrick Therapeutics. Read more
WuXi AppTec Press: Solid as a Rock: Creating a Strong Foundation for Developing First-in-Class Treatments to Fight Aggressive Cancers
May 10, 2017
An interview with Elaine Sullivan, Co-Founder & CEO, Carrick Therapeutics. Read more
Emory Tech Transfer Annual Celebration Winners 2017
Feb 28, 2017
Carrick wins “Deal of 2016”. Read more
Financial Times: Investors seek to build European oncology start-up
Oct 3, 2016
Leading cancer specialists in the UK and Ireland are aiming to build Europe’s leading oncology company backed by venture capitalists from the US and Europe. Read more
FierceBiotech: Oncology fledgling Carrick bags $95M Series A, names ex-AstraZeneca, Lilly exec as CEO
Oct 3, 2016
Carrick Therapeutics has wrapped up a $95 million (€85 million) Series A to fuel its ambition to grow into Europe’s leading oncology company. Read more
The Irish Times: Irish oncology start-up attracts $95m funding
Oct 3, 2016
A new Irish company treatment company, Carrick Therapeutics, has attracted $95 million (€84.5 million) in an initial funding round. Read more
Wall Street Journal: Cancer Drug Developer Carrick Therapeutics Launches With $95M
Oct 3, 2016
Carrick Therapeutics Ltd. is launching with $95 million from U.S. and European investors to develop therapies that disrupt molecular processes driving aggressive and drug-resistant cancers. Read more
Endpoints: $95M mega-round in hand, Elaine Sullivan sets out to build a European oncology player
Oct 3, 2016
A trans-Atlantic investment syndicate that includes Google has come together to bankroll a European oncology startup with a $95 million mega-round. Read more
Biospace: New Startup Carrick Therapeutics Launches With $95 Million and Taps Former AstraZeneca PLC (AZN)-Eli Lilly (LLY) Exec as CEO
Oct 3, 2016
Dublin-based Carrick Therapeutics blasts out of the gate, launching with $95 million in funding. Read more
Irish Business Insider: $95M funding for pioneering cancer researcher
Oct 3, 2016
A new venture which hopes to pioneer treatments for aggressive and resistant forms of cancer has been launched after securing funding worth $95m (£74m/€84.6m). Read more
